Eiger BioPharmaceuticals is a privately held biotechnology company that develops a novel antiviral therapy for Hepatitis Delta, a life-threatening, Orphan Disease with high unmet medical need and no approved therapy.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Its strategy is predicated upon time and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients.
Eiger BioPharmaceuticals is a privately held biotechnology company that develops a novel antiviral therapy for Hepatitis Delta, a life-threatening, Orphan Disease with high unmet medical need and no approved therapy.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Its strategy is predicated upon time and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients.
DNAnexus, Inc. specializes in cloud-based genome informatics and data management tools tailored for enterprises and organizations involved in genomic medicine. Founded in 2009 and headquartered in Mountain View, California, the company provides a platform that facilitates the analysis of raw sequencing data, integrates genomic data with clinical information, and enhances collaboration among researchers. Key offerings include the MOSAIC Microbiome platform for microbiome research, DNAnexus Apollo for clinico-genomic data exploration, DNAnexus Titan for data analysis, and DNAnexus Portals, which create secure online workspaces for collaborative projects. Additionally, the Clinico-Genomic Data Solution aims to enhance disease-specific datasets through partnerships with healthcare providers, improving screening and treatment pathways for complex diseases. DNAnexus serves a diverse clientele, including biopharmaceutical companies, genome centers, and diagnostic test providers, and has established a strategic alliance with WuXi NextCODE Genomics. The company also maintains additional offices in San Francisco, London, and Prague.
Apollo Endosurgery was founded upon the initial work of the Apollo Group, an international think tank of world-renowned gastroenterologists and surgeons from five leading universities (Mayo Clinic, Johns Hopkins, Medical University of South Carolina, University of Texas Medical Branch-Galveston and Chinese University-Hong Kong.) Disappointed with the pace of innovation in therapeutic flexible endoscopy, the Group assembled in 1998 (Timeline) with the goal to advance the new discipline; their specific focus was the use of long, flexible instruments deployed through a natural orifice in order to diagnose and potentially treat gastrointestinal disorders.
Cala Health is a bioelectronic medicine company focused on improving the treatment of chronic diseases through innovative neuromodulation therapies. The company specializes in wearable devices that provide individualized peripheral nerve stimulation, aiming to alleviate symptoms for patients with conditions such as essential tremor, which affects millions globally. Its primary product, Cala Trio, is a non-invasive therapy designed to offer transient relief from hand tremors in adults suffering from this condition. In addition to its current offerings, Cala Health is expanding its research and development efforts into therapies for neurology, cardiology, and psychiatry. Founded in 2013 and based in the San Francisco Bay Area, Cala Health is supported by prominent investors in healthcare and technology.
Geneoscopy, LLC is a diagnostic company based in Saint Louis, Missouri, focused on developing non-invasive solutions for gastrointestinal diseases, particularly colorectal cancer. Founded in 2015, Geneoscopy utilizes stool-derived eukaryotic RNA (seRNA) to create a multi-target RNA biomarker panel aimed at identifying colorectal cancer by detecting the effects of cancer-related DNA mutations. The company is committed to improving colorectal cancer screening compliance and facilitating early detection, thereby reducing the associated morbidity and mortality. By employing a novel methodology to extract human RNA transcripts from stool samples, Geneoscopy aims to provide a reliable alternative to traditional colonoscopies, which are often viewed as unpleasant and invasive. In addition to its colorectal cancer diagnostic test, Geneoscopy is also exploring other potential applications of its RNA technology for additional gastrointestinal conditions.
Exagen is a patient focused, discovery-driven life science company that addresses the unmet need for the accurate diagnosis and monitors patients affected by autoimmune rheumatic diseases. The company also provides AVISE tests that are specifically designed to provide objective information to physicians and patients for more accurate, efficient diagnosis, and better disease management. Exagen was established in 2002 and is headquartered in Vista, California.
Spacial is a San Francisco based company building accessory dwelling units for homeowner's backyards. The ADUs are beautiful, spacious and airy, and we utilize offsite construction increase speed to installation and decrease costs to homeowners, while delivering a home built to the same standard as their primary residence.
Imperative Care, Inc. is a medical technology company dedicated to enhancing acute stroke treatment. Founded in 2015 and based in Campbell, California, the company develops innovative solutions aimed at addressing critical needs in stroke care. Its primary offerings include the Large Distal Platform, a large diameter catheter designed to facilitate access to treatment sites for both ischemic and hemorrhagic strokes. Additionally, the ZOOM Aspiration System works in conjunction with the Large Distal Platform, providing a comprehensive solution for clot removal across various occlusion sizes, from the internal carotid artery to M2. By focusing on expediting and improving treatment effectiveness, Imperative Care aims to offer patients a greater chance for optimal recovery.
Match Marketing Group Inc. is a shopper marketing agency based in Mississauga, Canada, established in 2011. The company specializes in providing a comprehensive range of marketing solutions, including insights and strategy, digital and merchandising services, as well as activation and experiential marketing. They aim to inspire consumer purchases through seamless experiences that connect online and offline interactions. The agency's diverse clientele includes well-known brands such as adidas, GoGo Squeez, Malibu Rum, Lincoln Motor Company, and Ford. By focusing on the behaviors and preferences of connected shoppers, Match Marketing Group strives to enhance brand value and drive demand for its clients.
Personal Genome Diagnostics develops a patient-specific analysis of the cancer genome by using advanced tools and technologies. They were the first to sequence and analyze whole human cancer exomes and subsequently identified many alterations responsible for the development of cancer. They have described the principles underlying the genetic basis of human cancer and have developed novel technologies for non-invasive “liquid biopsy” approaches in cancer. Through PGDx, our founders bring their proprietary methods and expertise to research teams worldwide. The services help oncologists and translational scientists sequence and analyze cancer genomes and identify mutations to characterize aspects of the disease. Their expertise in genome analysis ranges from sample preparation and sequencing to data interpretation and analysis. They specialize in high-throughput next-generation sequencing and proprietary algorithms to identify alterations in complex cancer genomes and have developed novel technologies for non-invasive “liquid biopsy” approaches in cancer. Personal Genome Diagnostics was founded in 2010 and is based in Baltimore, Maryland, United States.
VSA Partners, Inc. is a branding and marketing services firm that provides a range of solutions including strategy, digital systems, design, and marketing. Founded in 1982 and originally known as Vogele Stoik Associates, Inc., the company rebranded in December 1984. Headquartered in Chicago, Illinois, VSA Partners also has offices in New York and San Francisco. The firm caters to clients globally, offering services such as visual identity, corporate communication, retail design, and packaging. These services are designed to enhance digital interactions, allowing audiences to engage, share, and purchase effectively.
Akoya Biosciences is a spatial biology company offering the most comprehensive, end-to-end solutions for high-parameter tissue analysis from discovery through clinical and translational research, enabling the development of more precise therapies for immuno-oncology and other drug development applications. The company has two industry-leading platforms that empower investigators and researchers to gain a deeper understanding of complex diseases such as cancer, and autoimmune or neurological disorders. The CODEX system is the only benchtop platform that can efficiently quantify more than 40 biomarkers and is ideally suited for biomarker discovery. The Phenoptics platform is the only end-to-end multiplexed immunofluorescence solution with the robustness and high throughput necessary for translational research and clinical trials.
Conformis is a medical technology company that uses its proprietary iFit® Image-to-Implant® technology platform to develop, manufacture, and sell joint replacement implants and instruments that are individually sized and shaped, which it refers to as personalized, individualized, or sometimes as customized, to fit each patient’s unique anatomy. Conformis offers a broad line of sterile, personalized knee and hip implants and single-use instruments delivered to hospitals and ambulatory surgical centers. In clinical studies, the Conformis iTotal® CR knee replacement system demonstrated superior clinical outcomes, including better function and greater patient satisfaction, compared to traditional, off-the-shelf implants. Conformis owns or exclusively in-licenses issued patents and pending patent applications that cover personalized implants and patient-specific instrumentation for all major joints.
DNAnexus, Inc. specializes in cloud-based genome informatics and data management tools tailored for enterprises and organizations involved in genomic medicine. Founded in 2009 and headquartered in Mountain View, California, the company provides a platform that facilitates the analysis of raw sequencing data, integrates genomic data with clinical information, and enhances collaboration among researchers. Key offerings include the MOSAIC Microbiome platform for microbiome research, DNAnexus Apollo for clinico-genomic data exploration, DNAnexus Titan for data analysis, and DNAnexus Portals, which create secure online workspaces for collaborative projects. Additionally, the Clinico-Genomic Data Solution aims to enhance disease-specific datasets through partnerships with healthcare providers, improving screening and treatment pathways for complex diseases. DNAnexus serves a diverse clientele, including biopharmaceutical companies, genome centers, and diagnostic test providers, and has established a strategic alliance with WuXi NextCODE Genomics. The company also maintains additional offices in San Francisco, London, and Prague.
Private Equity Round in 2018
Personal Genome Diagnostics develops a patient-specific analysis of the cancer genome by using advanced tools and technologies. They were the first to sequence and analyze whole human cancer exomes and subsequently identified many alterations responsible for the development of cancer. They have described the principles underlying the genetic basis of human cancer and have developed novel technologies for non-invasive “liquid biopsy” approaches in cancer. Through PGDx, our founders bring their proprietary methods and expertise to research teams worldwide. The services help oncologists and translational scientists sequence and analyze cancer genomes and identify mutations to characterize aspects of the disease. Their expertise in genome analysis ranges from sample preparation and sequencing to data interpretation and analysis. They specialize in high-throughput next-generation sequencing and proprietary algorithms to identify alterations in complex cancer genomes and have developed novel technologies for non-invasive “liquid biopsy” approaches in cancer. Personal Genome Diagnostics was founded in 2010 and is based in Baltimore, Maryland, United States.
Exagen is a patient focused, discovery-driven life science company that addresses the unmet need for the accurate diagnosis and monitors patients affected by autoimmune rheumatic diseases. The company also provides AVISE tests that are specifically designed to provide objective information to physicians and patients for more accurate, efficient diagnosis, and better disease management. Exagen was established in 2002 and is headquartered in Vista, California.